Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
复制标题
DOI：
10.1186/1472-6904-5-2
复制
发表时间：
2005-03-03
期刊：
影响因子：
--
通讯作者：
Sangdee C
中科院分区：
文献类型：
--
作者：
Anupongsanugool E;Teekachunhatean S;Rojanasthien N;Pongsatha S;Sangdee C
大豆中的异黄酮可能对绝经后健康有一些有益的影响。本研究的目的是比较绝经后泰国妇女口服单剂量大豆饮料和大豆提取物胶囊后血浆中大豆黄酮（大豆黄酮和染料木素）的药代动力学和生物利用度。我们在12名绝经后泰国妇女中进行了一项随机、两阶段、交叉的药代动力学研究。在第一阶段，每个受试者随机接受2个大豆提取物胶囊（含有大豆苷：染料木苷= 7.79：22.57 mg）或由15 g大豆粉制备的大豆饮料（含有大豆苷：染料木苷= 9.27：10.51 mg）。在第二阶段，受试者在至少1周的洗脱期后以相同方式接受替代制剂。在每个阶段大豆制剂给药前即刻和给药后0.5、1、2、4、6、8、10、12、24和32 h采集血样。采用高效液相色谱法测定血浆中大豆苷元和染料木素的浓度。采用TopFit 2.0版非房室模型分析软件，计算大豆苷元和染料木素的血药浓度（Cmax）、血药浓度达峰时间（Tmax）、血药浓度-时间曲线下面积（AUC）和半衰期（t1/2）。两种制剂之间染料木黄酮的Cmax/剂量、AUC 0 -32/剂量、AUC 0 -32/剂量、Tmax和t1/2的平均值无显著差异。对于大豆苷元的药代动力学参数，Cmax/剂量、Tmax和t1/2的平均值在两种制剂之间没有显著差异。尽管如此，大豆提取物胶囊给药后的平均AUC 0 -32/剂量和AUC 0 - 32/剂量略高于大豆饮料给药后的平均AUC 0 -32/剂量和AUC 0 - 32/剂量（但显著，p < 0.05）。大豆苷元的生物利用度，这是调整的给药剂量（AUC/剂量），单次口服大豆饮料后，略低于（但显着）大豆提取物胶囊，而从两种大豆制剂的染料木素给药剂量调整的生物利用度是相当的。大豆苷元和染料木素的其他药代动力学参数，包括调整剂量的Cmax，Tmax和t1/2，两种大豆制剂之间没有差异。
Isoflavones from soybeans may provide some beneficial impacts on postmenopausal health. The purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai women. We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai women. In the first phase, each subject randomly received either 2 soy extract capsules (containing daidzin : genistin = 7.79 : 22.57 mg), or soy beverage prepared from 15 g of soy flour (containing daidzin : genistin = 9.27 : 10.51 mg). In the second phase, the subjects received an alternative preparation in the same manner after a washout period of at least 1 week. Blood samples were collected immediately before and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 h after administration of the soy preparation in each phase. Plasma daidzein and genistein concentrations were determined by using high performance liquid chromatography (HPLC). The pharmacokinetic parameters of daidzein and genistein, i.e. maximal plasma concentration (Cmax), time to maximal plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (t1/2), were estimated using the TopFit version 2.0 software with noncompartmental model analysis. There were no significant differences in the mean values of Cmax/dose, AUC0–32/dose, AUC0-∝/dose, Tmax, and t1/2 of genistein between both preparations. For pharmacokinetic parameters of daidzein, the mean values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations. Nonetheless, the mean AUC0–32/dose and AUC0-∝/dose after administration of soy extract capsules were slightly (but significantly, p < 0.05) higher than those of soy beverage. The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules, whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were comparable. The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the dose, Tmax and t1/2, were not different between both soy preparations.